GeneSeq HIV is a highly accurate genotypic HIV drug resistance assay. The test is performed using state-of-the-art technology and the results are determined using the most recently updated HIV mutation information and information from scientific research and Monogram's resistance experts.

The report form includes drug resistance information for all of the approved nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and protease inhibitors (PIs).

Features and benefits of the GeneSeqT HIV assay:

• Utilizes a regularly updated algorithm based on published scientific research and proprietary information from Monogram's extensive phenotype-genotype database
• Over 99% reproducibility
• Can be performed on samples with viral loads as low as 500 copies/mL
• Sensitivity to detect mixtures as low as 10% of the total viral population
• Custom software and at least two clinical laboratory scientists to analyze every position of the nucleotide sequence
• Includes HIV-1 subtype reporting

Genotypic Predictors of Response to Lopinavir/ritonavir (LPV/r) in Clinical Practice. (refer to attached pdf titled LPVr CBIG IAS03) Rice, H., Nadler, J., Schaenman, J., Hawkins, T., Cohen, C., Harrington, R., Kitahata, M., Rode, R., Kempf, D., and Zolopa, A.

Reference: Improving Lopinavir Genotype Algorithm Through Phenotype Correlations: Novel Mutation Patterns and Amprenavir Cross-resistance. N. Parkin et al; AIDS, 17(7):955-961, May 2, 2003.

For more information on Monogram assays, services and pricing, please contact us.